Effects of preventive long-term treatment with strontium ranelate and zoledronic acid to ovariectomized rats on bone microstructure

2014 ◽  
Author(s):  
Marta Martin-Fernandez ◽  
Marina Gomez-Chinchon ◽  
David Guede ◽  
Jose Ramon Caeiro ◽  
Manuel Diaz-Curiel ◽  
...  
Keyword(s):  
Zoledronic Acid ◽  
Strontium Ranelate ◽  
Bone Microstructure ◽  
Term Treatment ◽  
Ovariectomized Rats ◽  
Long Term Treatment

scholarly journals Response to Zoledronic Acid Infusion in Children With Fibrous Dysplasia

2020 ◽  
Vol 8 ◽  
Author(s):  
Sujit Kumar Tripathy ◽  
Shakti Swaroop ◽  
Sandeep Velagada ◽  
Debashree Priyadarshini ◽  
Rashmi Ranjan Das ◽  
...  
Keyword(s):  
Zoledronic Acid ◽  
Fibrous Dysplasia ◽  
Term Treatment ◽  
Acid Infusion ◽  
Café Au Lait Spots ◽  
Long Term Treatment ◽  
Radiological Response ◽  
Radiological Changes

Objective: This retrospective study evaluated the outcome and safety of long-term treatment with zoledronic acid, in both polyostotic and mono-ostotic fibrous dysplasia (FD) of children.Methods: The case records of children and adolescents with symptomatic FD who received zoledronic acid (0.1 mg/kg IV infusion over 1 h) and have completed at least 2 years follow-up were analyzed. The relevant details were recorded in a predesigned chart. Clinical assessment [pain assessment by visual analog scale (VAS) and incidence of new fracture], radiological changes (cortical thickening, ossification, and decrease in the diameter of the osteolytic lesions) and biochemical parameters [alkaline phosphatase (ALP)] were used to evaluate the improvement.Results: The mean age of presentation was 9.1 years, with four males and six females. All patients had symptomatic FD in the lower limb with complaints of pain, tenderness, swelling, or deformity. Four children had associated pathological fracture. The radiological evaluation with bone scan revealed polyostotic involvement in eight patients and mono-ostotic involvement in two patients. Three patients had associated systemic features like café-au-lait spots or precocious puberty. The fracture united within 3 months and the radiological improvement was evident in the form of filling of the osteolytic defect. The pain score in six patients showed significant improvement (VAS < 3). The ALP level decreased to 544.12 ± 47.35 IU/L from an initial value of 895.75 ± 79.64 IU/L (p = 0.04) at 12 months. One patient had symptomatic hypocalcaemia after zoledronic acid infusion.Conclusion: The clinical and radiological response of zoledronic acid treatment in FD of children is promising. Further randomized control trials with a larger sample size are required to establish this drug as a first-line medical treatment in FD.

Re: “Effect of long-term treatment with strontium ranelate on bone strontium content” by Bärenholdt et al. (Bone, 2009)

Bone ◽  
2009 ◽  
Vol 45 (5) ◽  
pp. 1024-1025 ◽  
Author(s):  
Patricia Belissa-Chatelain ◽  
Isabelle Dupin-Roger ◽  
Fabienne Cournarie ◽  
Yannis Tsouderos
Keyword(s):  
Strontium Ranelate ◽  
Term Treatment ◽  
Strontium Content ◽  
Long Term Treatment

scholarly journals Effects of Long-Term Treatment with Estradiol and Estrogen Receptor Subtype Agonists on Serotonergic Function in Ovariectomized Rats

2015 ◽  
Vol 103 (3-4) ◽  
pp. 269-281 ◽  
Author(s):  
Saloua Benmansour ◽  
Opeyemi S. Adeniji ◽  
Anthony A. Privratsky ◽  
Alan Frazer
Keyword(s):  
Estrogen Receptor ◽  
Term Treatment ◽  
Ovariectomized Rats ◽  
Receptor Subtype ◽  
Long Term Treatment ◽  
Serotonergic Function

scholarly journals Treatment of patients with osteoporosis: issues of therapy duration, adherence, and replacement

2018 ◽  
Vol 12 (4) ◽  
pp. 59-64
Author(s):  
N. V. Toroptsova
Keyword(s):  
Chronic Disease ◽  
Zoledronic Acid ◽  
Adverse Reactions ◽  
Alternative Therapy ◽  
Term Treatment ◽  
Low Energy ◽  
Drug Holiday ◽  
Increased Risk ◽  
Long Term Treatment

Osteoporosis is a chronic disease requiring long-term treatment aimed at reducing the risk of low-energy fractures, by improving the quality and strength of bones when taking this or that drug. Bisphosphonates (BPs) are deposited in the bone, so that they have an aftereffect. Due to the increased risk of adverse reactions with BPs, the author considers that the patients may take a drug holiday or be switched to alternative therapy. Denosumab may be used continuously for years and, unlike BPs, does not require discontinuation. It is effective in both untreated and already BP-treated patients. At the same time, when the treatment is discontinued, the effect of denosumab is reversible; therefore, oral BP or intravenous zoledronic acid is recommended to maintain the achieved effect.

scholarly journals Long-Term Treatment of Indomethacin Reduces Vertebral Bone Mass and Strength in Ovariectomized Rats

1997 ◽  
Vol 12 (11) ◽  
pp. 1844-1850 ◽  
Author(s):  
Hitoshi Saino ◽  
Toshikatsu Matsuyama ◽  
Junichi Takada ◽  
Tohru Kaku ◽  
Seiichi Ishii
Keyword(s):  
Bone Mass ◽  
Term Treatment ◽  
Ovariectomized Rats ◽  
Vertebral Bone ◽  
Long Term Treatment ◽  
Vertebral Bone Mass
Sign in / Sign up

Export Citation Format

Share Document